XOMA Corporation
XOMA Corporation is a biotechnology company that operates as a royalty aggregator, discovering and developing antibody-based therapies and licensing future economics or rights to pre-commercial candidates to pharmaceutical and biotechnology partners. It maintains a pipeline of monoclonal antibody programs and provides antibody discovery, optimization, and development technologies under collaboration with partners. Notable candidate programs include X213, an allosteric prolactin inhibitor; XMetA, an insulin receptor–activating antibody for long-acting reduction of hyperglycemia in Type 2 diabetes; an IL-2–based therapy for metastatic melanoma and renal cell carcinoma; and a PTH1R program addressing primary hyperparathyroidism and related conditions. The company collaborates with large pharma entities such as Novartis, Rezolute, and Takeda to advance clinical development. Founded in 1981, XOMA is headquartered in Emeryville, California, and operates with regional reach across the United States, Europe, Asia Pacific, and other markets.
3 past transactions
Pulmokine
Acquisition in 2024
Pulmokine is a privately held biopharmaceutical company dedicated to developing innovative therapies for challenging lung conditions, particularly pulmonary arterial hypertension and related disorders such as pulmonary arterial fibrosis, sarcoidosis, and lung cancer. The company leverages its expertise in pulmonary disease and kinase inhibitor technology to create targeted treatments that aim to improve patient outcomes for those suffering from these serious conditions. Through its focused research and development efforts, Pulmokine endeavors to address unmet medical needs in the field of pulmonary medicine.
Dare Bioscience
Post in 2024
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.
Kinnate Biopharma
Acquisition in 2024
Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.